Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of CF101 to Treat Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 to 70 years of age, inclusive;~* Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area involvement ≥10%, as judged by the Investigator;~* Duration of psoriasis of at least 6 months;~* PASI score ≥10;~* Body weight ≤100 kg;~* Candidate for systemic treatment or phototherapy for psoriasis;~* ECG is normal or shows abnormalities which, in the judgment of the Investigator, are not clinically significant;~* Females of child-bearing potential must have a negative serum pregnancy test at screening;~* Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the Investigator (for example oral contraceptive pills plus a barrier method) to be eligible for, and continue participation in, the study;~* Ability to complete the study in compliance with the protocol; and~* Ability to understand and provide written informed consent.~Exclusion Criteria:~* Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis;~* Treatment with systemic retinoids, corticosteroids, or immunosuppressants (e.g., methotrexate, cyclosporine) within 6 weeks of the Baseline visit;~* Treatment with high potency topical corticosteroids (Class I-III), keratolytics, or coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the Baseline visit;~* Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated need for either of these therapies during the study period;~* Treatment with a biological agent (including etanercept, adalimumab, efalizumab, infliximab, or alefacept) within a period of time equal to 5 times its circulating half-life, or 30 days, whichever is longer, prior to the Baseline visit;~* History of poor clinical response to methotrexate after an adequate regimen and duration of treatment;~* Treatment with systemic nonsteroidal anti-inflammatory drugs, beta-blockers, lithium, hydroxychloroquine, chloroquine, or systemic terbinafine within 2 weeks of the Baseline visit, or anticipated need for such drugs during the study period;~* Presence or history of uncontrolled asthma;~* Presence or history of uncontrolled arterial hypertension or symptomatic hypotension;~* Significant cardiac arrhythmia or conduction block, congestive heart failure (New York Heart Association Class 3-4), or any other evidence of clinically significant heart disease or clinically significant findings on screening electrocardiogram;~* Hemoglobin level \<9.0 gm/L;~* Platelet count \<125,000/mm\^3;~* White blood cell count \<3500/mm\^3;~* Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal;~* Liver aminotransferase levels greater than 2 times the laboratory's upper limit of normal;~* Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the Investigator;~* History of malignancy within the past 5 years (excluding basal cell carcinoma of the skin and ≤3 cutaneous squamous cell carcinomas, all of which have been completely excised);~* Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study;~* Participation in another investigational drug or vaccine trial concurrently or within 30 days; or within 5 half lives of a biological investigational product, whichever is longer;~* Other conditions which would confound the study evaluations or endanger the safety of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CF101 1 mg (Type: EXPERIMENTAL): None
- CF101 2mg (Type: EXPERIMENTAL): None
- CF101 4mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).